Psyence Biomedical Ltd

“Psyence Biomedical: First Nasdaq Company to GMP‑Produce High‑Purity Ibogaine, No Debt, $12M Cash”

Nasdaq‑listed Psyence Biomedical produces GMP‑compliant ibogaine HCl, a first for the industry, while holding $12 M cash and no debt—boosting its edge in psychedelic therapy research.

05/01/2026, 15:22

3 minutes to read

“Psyence Biomedical’s Phase IIb Psilocybin Breakthrough: Debt-Free, Cash‑Rich, Ready to Revolutionize Mental Health”

Discover how Psyence Biomedical’s debt‑free, $9.5 M‑cash position fuels its leap to Phase IIb psilocybin trials, positioning it as a rising force in psychedelic therapeutics.

19/12/2025, 13:09

3 minutes to read

How Psyence Biomedical’s Psilocybin Longevity Program Could Revolutionize Aging

Discover how Psyence Biomedical is pioneering psilocybin‑based longevity research, targeting aging biomarkers, and unlocking a multi‑billion‑dollar anti‑aging market.

25/11/2025, 16:20

3 minutes to read

Psyence Biomedical Soars with Breakthrough in Ibogaine Production

Psyence Biomedical Ltd. has achieved a breakthrough in ibogaine production, a significant advancement in biotechnology that has led to a surge in the company’s stock price and positions it as a leader in the sector.

31/07/2025, 14:15

2 minutes to read